# Sutro Biopharma, Inc.: overview STRO · Nasdaq · CIK 1382101 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/stro.md) · [Financials](/companies/stro/financials.md) · [Filings](/companies/stro/filings.md) · [Insiders](/companies/stro/insiders.md) Latest reported revenue: [$9.8m](/filings/0001193125-26-345748.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-345748). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [8.5](/filings/0001193125-25-270036.md) | [14.8 d](/filings/0001193125-26-119873.md) | [17.4](/filings/0001193125-26-224170.md) | [63.7](/filings/0001193125-26-345748.md) | [9.7](/filings/0001193125-25-270036.md) | [11.6 d](/filings/0001193125-26-119873.md) | [14.5](/filings/0001193125-26-224170.md) | [9.8](/filings/0001193125-26-345748.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(797.2%)](/filings/0001193125-25-270036.md) | [(440.7%) d](/filings/0001193125-26-119873.md) | [(393.8%)](/filings/0001193125-26-224170.md) | [(5.2%)](/filings/0001193125-26-345748.md) | [(499.9%)](/filings/0001193125-25-270036.md) | [(326.7%) d](/filings/0001193125-26-119873.md) | [(204.2%)](/filings/0001193125-26-224170.md) | [(303.8%)](/filings/0001193125-26-345748.md) | | Net margin | % | [(572.6%)](/filings/0001193125-25-270036.md) | [(489.2%) d](/filings/0001193125-26-119873.md) | [(436.6%)](/filings/0001193125-26-345748.md) | [(18.0%)](/filings/0001193125-26-345748.md) | [(586.6%)](/filings/0001193125-25-270036.md) | [(401.5%) d](/filings/0001193125-26-119873.md) | [(265.0%)](/filings/0001193125-26-345748.md) | [(391.6%)](/filings/0001193125-26-345748.md) | | Diluted EPS | $ per share | [(0.59)](/filings/0001193125-25-270036.md) | not reported | [(9.08)](/filings/0001193125-26-224170.md) | [(1.35)](/filings/0001193125-26-345748.md) | [(0.67)](/filings/0001193125-25-270036.md) | not reported | [(2.94)](/filings/0001193125-26-224170.md) | [(2.33)](/filings/0001193125-26-345748.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [61.9](/filings/0000950170-24-035949.md) | [67.8](/filings/0000950170-25-038884.md) | [154](/filings/0000950170-25-038884.md) | [62.0](/filings/0001193125-26-119873.md) | [102](/filings/0001193125-26-119873.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(159.2%)](/filings/0000950170-24-035949.md) | [(190.3%)](/filings/0000950170-25-038884.md) | [(58.1%)](/filings/0000950170-25-038884.md) | [(384.3%)](/filings/0001193125-26-119873.md) | [(154.5%)](/filings/0001193125-26-119873.md) | | Net margin | % | [(170.6%)](/filings/0000950170-24-035949.md) | [(175.9%)](/filings/0000950170-25-038884.md) | [(69.5%)](/filings/0000950170-25-038884.md) | [(366.6%)](/filings/0001193125-26-119873.md) | [(186.5%)](/filings/0001193125-26-119873.md) | | Diluted EPS | $ per share | [(2.29)](/filings/0000950170-24-035949.md) | [(2.35)](/filings/0000950170-25-038884.md) | [(1.78)](/filings/0000950170-25-038884.md) | [(29.40)](/filings/0001193125-26-119873.md) | [(22.49)](/filings/0001193125-26-119873.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/stro/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $43.3m | 1,304,846 | | Added +589,539 | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $41.6m | 1,251,788 | | Unchanged | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $38.9m | 1,172,487 | | Added +102,968 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $37.3m | 1,122,655 | | Added +889,971 | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $35.3m | 1,062,872 | | Unchanged | | [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $29.0m | 872,558 | | Unchanged | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $24.7m | 743,944 | | Reduced −57,200 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $23.6m | 711,162 | | Added +245,370 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $23.0m | 694,219 | | Reduced −26,223 | | [EVENTIDE ASSET MANAGEMENT, LLC](/funds/1442891.md) | 2026-06-30 | $19.4m | 585,262 | | Reduced −130,045 | ## Recent filings [All 611 filings](/companies/stro/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-12 | 07:30 ET | [10-Q](/filings/0001193125-26-345748.md) | Quarterly report, period 2026-06-30 | 0001193125-26-345748 | | 2026-08-12 | 07:15 ET | [8-K](/filings/0001193125-26-345733.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-345733 | | 2026-06-08 | 16:01 ET | [8-K](/filings/0001193125-26-261658.md) | 5.07 Shareholder vote results | 0001193125-26-261658 | | 2026-05-14 | 16:30 ET | [10-Q](/filings/0001193125-26-224170.md) | Quarterly report, period 2026-03-31 | 0001193125-26-224170 | | 2026-05-14 | 16:15 ET | [8-K](/filings/0001193125-26-224065.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-224065 | | 2026-04-22 | 16:05 ET | [DEF 14A](/filings/0001193125-26-170354.md) | Proxy statement, period 2026-06-05 | 0001193125-26-170354 | | 2026-03-23 | 16:44 ET | [10-K](/filings/0001193125-26-119873.md) | Annual report, period 2025-12-31 | 0001193125-26-119873 | | 2026-03-23 | 16:32 ET | [8-K](/filings/0001193125-26-119844.md) | 1.02 Termination of a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-119844 | | 2026-02-10 | 17:16 ET | [8-K](/filings/0001193125-26-044934.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-044934 | | 2025-12-17 | 16:38 ET | [8-K](/filings/0001193125-25-322859.md) | 8.01 Other events | 0001193125-25-322859 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-119873.md), filed Mar 23, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3548f0a4-fbd1-4646-99cd-065bd58bbf56) ## About the filer - CIK: 1382101 - Tickers: STRO - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.